Komori
Sysmex (6869) · InitiativeFirst stated

Full automation and standardization of genetic testing of cancer tissue

First written in FY2019-Q2. . Latest entry: FY2019-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Full automation and standardization of genetic testing for cancer tissueA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2019-Q2First statedAnnual report

    「August 2018: We jointly developed with 凸版印刷株式会社 and 株式会社理研ジェネシス the research-use genetic analyzer LW-100 and related reagents, which fully automate testing for genetic mutations in cancer tissue. The 3 companies began providing the system for research use and are actively verifying its clinical utility with a view to early clinical commercialization, aiming to standardize genetic testing using cancer tissue specimens.」

    Began providing LW-100 and related reagents, jointly developed with Toppan Printing and RIKEN Genesis, for research use, with the aim of early practical application in clinical settings, validation of clinical utility, and standardization of genetic testing using cancer tissue specimens.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sysmex yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Full automation and standardization of genetic testing of cancer tissue | SYSMEX CORPORATION (6869) | Komori